Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Bionano Genomics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $14.9 million for Q1 2021.

• In Q1 2021, Non-Current Debt changed N/A year-over-year to $14.9 million; the TTM figure through Mar 2021 stood at $14.9 million (changed N/A YoY), while the FY2020 annual figure was $16.3 million, changed N/A from the prior year.
• Non-Current Debt came in at $14.9 million for Q1 2021 at Bionano Genomics, down from $16.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $18.8 million in Q3 2019 to a low of $1.8 million in Q2 2020.
• A 4-year average of $12.1 million and a median of $14.9 million in 2021 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt surged 108.44% in 2019 and sank 90.55% in 2020, its largest moves.
• Bionano Genomics' Non-Current Debt stood at $9.0 million in 2018, then surged by 107.96% to $18.8 million in 2019, then retreated by 13.06% to $16.3 million in 2020, then fell by 8.94% to $14.9 million in 2021.
• According to Business Quant data, Non-Current Debt over the past three periods registered $14.9 million, $16.3 million, and $1.8 million for Q1 2021, Q4 2020, and Q3 2020 respectively.

Peer Comparison